NASDAQ
1.27USD
-0.04 (-2.67%)
We have scored 5 news catalysts on Microbot Medical Inc. (MBOT) over the past 12 months. The biggest single-day move next to one of them came Sep 25, 2026, when MBOT closed −3.1%: “Microbot Medical® Highlights Growth Strategy”. Coverage across the window leans positive (average ticker sentiment +0.58). Most of the impact sits in short squeeze potential and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
58.1M
P/E
—
EPS
—
Beta
1.03
52W range
1.26-3.46
Day range
1.26–1.33
Open
1.32
Prev close
1.31
Volume
445.6K
Avg volume
1.1M
Dividend
0.00
IPO
1992-03-25
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Microbot Medical Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for MBOT: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompassing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.
